ARMP Armata Pharmaceuticals, Inc. 10-Q 2026-09-30 section summaries

Armata Pharmaceuticals (ARMP) — Q3 and nine months ended September 30, 2026

Business and development

Armata is a late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapies for antibiotic-resistant and difficult-to-treat bacterial infections. It operates as one reportable segment. Revenue comes from grants and awards, not commercial product sales, and the company remains dependent on external financing.

Consolidated results

Grant revenue increased 173% in Q3 and 69% for the first nine months, principally reflecting the government-funded MTEC award. Higher personnel costs contributed to the year-to-date increases in R&D ($9.405M versus $6.893M) and G&A ($6.785M versus $3.733M).

The large swing in other income primarily reflects remeasurement of the Convertible Loan: Armata recorded a fair-value gain of $69.595M in Q3 and $59.551M for 9M 2026, compared with losses of $14.643M and $15.191M in the corresponding 2025 periods. The $30.0M-principal loan had a Level 3 fair value of $94.309M at September 30, 2026, versus $153.860M at year-end 2025; the 2026 valuation assumed full conversion into equity. Because remeasurement runs through earnings, reported net income is highly valuation-sensitive. For diluted EPS, the fair-value gain was excluded, resulting in diluted common-stockholder losses of $14.738M for Q3 and $45.899M for 9M. Diluted weighted-average shares were 62.679M and 61.923M, including 25.498M and 25.101M Convertible Loan conversion shares, respectively.

Cash flow

Cash, cash equivalents and restricted cash increased $8.359M to $22.437M, including $28.494M of financing cash flow. Stock-based compensation was $6.682M for 9M 2026, versus $1.978M.

Financial position

Debt carrying values included a $94.309M current Convertible Loan and no noncurrent balance (versus $153.860M noncurrent at year-end), plus current and noncurrent term debt of $83.862M and $43.299M (versus none current and $103.061M noncurrent). Operating lease liabilities totaled $30.113M. Lease minimum payments were $55.734M, including $25.621M of interest; the weighted-average remaining lease term was 10.2 years. The company recorded a $5.4M Marina del Rey right-of-use asset impairment in 2025, but no long-lived asset impairment in 9M 2026.

Financing, shares and liquidity

The 2026 amendments to Innoviva-related credit agreements were accounted for as a troubled debt restructuring because Armata was experiencing financial difficulty and the lender granted a concession. The amendments extended the Convertible Loan and certain term-loan maturities to June 1, 2027; certain warrant expirations were extended to January 26, 2031. A revised 36.19% effective interest rate applies prospectively to amended term loans, with no restructuring gain recorded.

Term loans totaled $110.0M principal, generally bear 14.0% stated annual interest, are secured by substantially all company and subsidiary-guarantor assets, and require principal and accrued interest at maturity. The 2023, 2024 and March 2025 loans mature June 1, 2027; the August 2025 and May 2026 loans mature January 11, 2029. The Convertible Loan bears 8.0% stated interest and matures June 1, 2027; accrued stated interest was approximately $9.1M. The agreements include restrictive covenants, mandatory prepayments and defaults that include material deviation from the operating budget. The December 2025 ATM permits up to $100M of aggregate sales; 338,000 shares were sold for approximately $2.4M net proceeds in 9M 2026.

At September 30, 2026, outstanding awards and conversion-related shares included 6.263M options, 10.655M warrants, 0.085M unvested RSUs and 25.697M shares reserved for Convertible Loan conversion. Total shares reserved for future issuance, including plan and ESPP availability, were 46.694M. Unrecognized option and RSU compensation was $12.9M, expected to be recognized over approximately 2.1 years.

Management said $18.3M of cash and cash equivalents would not fund operations for the 12 months after issuance of the statements and disclosed substantial doubt about Armata’s ability to continue as a going concern. The company had an accumulated deficit of $487.9M, expects further losses, and says its plans to raise capital are not within its control or considered probable. Failure to secure financing could require cuts to R&D or operations; equity financing could dilute shareholders, while collaborations or licenses could require relinquishing product rights.

Development funding

The MTEC award increased by $3.7M to $32.4M in September 2026 and was extended through December 31, 2026. It supports AP-SA02 bacteremia development, FDA End-of-Phase 2 preparation, and planned Phase 3 readiness and execution. The award is cost-reimbursable; commercialization or licensing of funded intellectual property may trigger capped royalties or assessment fees. The Cystic Fibrosis Foundation’s award of up to $5.0M for AP-PA02 had been fully recognized by December 2023, with final payment received in 2024; its terms include potential future payments and license rights under specified circumstances.

Business and clinical development

Armata is a late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapies for antibiotic-resistant and difficult-to-treat infections. It has completed three Phase 2 trials. Its Los Angeles facility includes approximately 10,000 square feet of licensed cGMP manufacturing suites; the company says manufacturing improvements have increased phage titers and purity and improved production efficiency. These capabilities are intended to support future clinical supply and commercialization, but are not commercial outcomes.

• AP-PA02 for chronic P. aeruginosa lung infections: In the completed Phase 1b/2a SWARM-P.a. cystic fibrosis study, inhaled AP-PA02 was reportedly well tolerated, with sputum exposure rising with dose and bacterial-load findings suggesting a dose-related reduction. In the completed Phase 2 Tailwind study for non-CF bronchiectasis, the primary endpoint was not significant in either cohort analyzed separately. A post-hoc pooled analysis (33 active, 15 placebo) found lower sputum P. aeruginosa counts with AP-PA02 at days 17 (p=0.05) and 24 (p=0.015); the company cautions that these pooled findings do not replace the non-significant prespecified analyses. Further development, potentially a Phase 3 trial, depends on obtaining additional funding.

• AP-SA02 for complicated S. aureus bacteremia: In the Phase 1b/2a diSArm study, the company reported better clinical-response results with AP-SA02 plus best available antibiotic therapy (BAT) than placebo plus BAT. At day 12, investigator-assessed response was 88% (21/24) versus 58% (7/12; p=0.047); at BAT test of cure, investigator-assessed response was 100% versus 75% (p=0.017). Results were also reported in MRSA and MSSA infections. AP-SA02 was reportedly well tolerated, with no study-drug-related serious adverse events; the small study and missing assessments warrant caution.

  FDA’s January 2026 End-of-Phase 2 response supported advancing AP-SA02 to Phase 3 and provided study-design and CMC guidance. The company received QIDP, Fast Track and Breakthrough Therapy designations in 2026. Its proposed Phase 3 superiority trial would randomize approximately 550 adults 1:1 to AP-SA02 plus BAT or placebo plus BAT, with a goal of retaining approximately 250 per arm through the primary assessment. The planned endpoint is clinical response at Day 70; AP-SA02 would be given intravenously every six hours for seven days. Initiation is expected in 2H 2026, subject to FDA concurrence. Trial preparation includes completed engineering runs and a Q3 cGMP production run and vialing of clinical-trial material.

• Other opportunities: Armata is exploring preclinical IV AP-PA03 for acute P. aeruginosa infections, including ventilator-associated pneumonia; an IND and clinical development depend on funding. Potential AP-SA02 expansion areas include frontline treatment, shorter antibiotic courses, pediatric patients, and prosthetic-joint or wound infections.

Financial results

Dollar amounts in millions.

Grant revenue increased 173.6% in Q3 and 69.4% in 9M, reflecting MTEC reimbursement of AP-SA02 costs. The reported earnings swing principally reflects noncash Convertible Loan fair-value gains, driven mainly by stock-price movements, rather than operating profitability. The 2026 valuation model assumed a 100% probability of conversion, increasing earnings sensitivity to the share price.

Nine-month R&D costs included approximately $0.2 million of clinical-trial costs versus $1.8 million a year earlier, mainly because the AP-SA02 Phase 2 study was completed. This decline was partly offset by higher manufacturing-related external costs ($3.097 million versus $1.859 million), personnel costs ($9.405 million versus $6.893 million, including a $2.0 million increase in stock-based compensation), and facilities and overhead costs ($7.852 million versus $7.101 million). Total 9M stock-based compensation was $6.7 million versus $2.0 million.

Cash flows, funding and principal risks

Cash and cash equivalents were $18.3 million at September 30, 2026. Management says available cash is insufficient to fund operations for the 12 months following issuance of the 10-Q and identifies substantial doubt about the company’s ability to continue as a going concern. Armata has no product revenue and expects to need additional capital; unavailable or unfavorable financing could delay or curtail programs or force other adverse strategic actions.

A May 2026 Innoviva Sub loan provided $25.0 million at 14.0% annual interest, secured by substantially all company and domestic subsidiary-guarantor assets, with principal and accrued interest due January 11, 2029. A separate August 2025 loan provided $15.0 million on similar terms. Amendments extended maturities under earlier credit agreements to June 1, 2027. Under its $100 million ATM program, Armata sold 338,000 shares for approximately $2.4 million net proceeds in 9M 2026; option exercises generated another $1.2 million.

MTEC’s cumulative award increased to $32.4 million and was extended through December 31, 2026, supporting diSArm and Phase 3 preparation and execution. The company reported no off-balance-sheet arrangements. Its financial statements rely on estimates including those for the Convertible Loan, stock-based compensation, R&D accruals and asset impairment; no material changes to critical accounting policies were reported.

ARMP is a smaller reporting company and is not required to provide the quantitative and qualitative disclosures about market risk in this section. Accordingly, the section reports no market-risk metrics or material changes.

Controls and Procedures

As of September 30, 2026, the CEO and CFO/PFO concluded that the company’s disclosure controls and procedures were effective. During the quarter ended September 30, 2026, no changes to internal control over financial reporting materially affected, or were reasonably likely to materially affect, those controls. Management cautioned that controls provide reasonable—not absolute—assurance and involve considerations of cost and judgment.

The company reports no material changes to the risk factors described in Item 1A of Part I of its 2025 Form 10-K. This section provides no additional risk details or financial metrics.

For the three months ended September 30, 2026, no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.